[ASCO] AZ CEO predicts 우리카지노 바카라사이트 cure within a decade, emphasizing weight management has role importance in treatment

[by Lee, Young Sung] AstraZeneca (AZ) has projected that within the next decade, achieving a 'cure for 우리카지노 바카라사이트' will become possible. Historically, chemotherapy was the sole treatment option for 우리카지노 바카라사이트, however, emerging options such as antibody-drug conjugates (ADCs) and bispecific antibodies are expending therapeutic possibilities and generating renewed optimism. Additionally, AstraZeneca has identified obesity as a key target in 우리카지노 바카라사이트 treatment, underscoring its commitment to developing therapeutics that address weight-related factors. The company has an ambitious goal of releasing 20 novel drugs by 2030 and reaching annual sales of USD 80 billion (approximately KRW 111 trillion).

Pascal Soriot, CEO of Astr우리카지노 바카라사이트eneca, delivered this statement during a press conference convened on May 30 (local time), preceding the opening of the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The conference, which is scheduled to take place in Chicago, USA, will run for five days, concluding on June 3 (local time).

“The progress achieved in the field of oncology over the past 10 to 15 years is truly remarkable and beyond description,” remarked 우리카지노 바카라사이트. “Previously, chemotherapy was the only available option, but now we have access to a wide array of new technologies, and this presentation will demonstrate the outcomes that these technologies can actually deliver.”

“I believe that the day when we can cure 우리카지노 바카라사이트 is not far off,” he further emphasized. “We are already witnessing success in treating some 우리카지노 바카라사이트s, and within approximately ten years, many more will move beyond sustainable remission to actual cures.”

Soriot went on to elaborate on AstraZeneca’s drug development strategy, highlighting the proprietary technology at its core. Notably, the company’s decision to target ‘weight’ as a key factor in anti우리카지노 바카라사이트 treatment has attracted significant attention.

“Although weight management may not appear to be directly associated with 우리카지노 바카라사이트, in reality, it is one of the primary risk factors for the disease,” Soriot further explained. “Effective weight management is crucial not only for cardiovascular health but also for reducing the incidence of 우리카지노 바카라사이트.”

“We are actively broadening our portfolio to include therapeutics that address 우리카지노 바카라사이트 and associated risk factors, such as cholesterol,” he added.

Furthermore, AstraZeneca provided an overview of 우리카지노 바카라사이트s ADC and hydroconjugate (HDC) portfolio. “These technologies are anticipated to eventually replace or complement chemotherapy in the long term, and in some cases, they may even serve as alternatives to radiotherapy,” Soriot stated.

Regarding the bispecific antibody portfolio, he added, “Our portfolio includes DIGIT-based bispecific antibodies as well as CTLA-4-based bispecific antibodies.” DIGIT-based bispecific antibodies are a platform technology developed by AstraZeneca, aimed at precisely targeting 우리카지노 바카라사이트 cells and inducing strong immune responses.

He also conveyed his expectations for the cell gene therapy (CGT) sector, noting, “AstraZeneca has built a dedicated portfolio for cell therapy.” Soriot further elaborated, “We are making large-scale investments in the development of T cell engagers, w우리카지노 바카라사이트h clinical trials already underway. We anticipate advancing to Phase 3 and beginning patient applications w우리카지노 바카라사이트hin the next two to three years.”

As part of this strategic effort, Soriot introduced ESO Biotec, a company recently acquired by Astr우리카지노 바카라사이트eneca. ESO Biotec is focused on developing in vivo cell therapy technology.

"The principal challenge w우리카지노 바카라사이트h current cell therapy lies in the logistics, which involve a highly intricate process of extracting cells, transporting them to a manufacturing facil우리카지노 바카라사이트y, and then reintroducing them into the patient," Sorio remarked. "The technology we have acquired enables us to directly generate therapeutic cells in the patient's body. Should this technology reach commercialization, 우리카지노 바카라사이트 will pave the way for true 'personalized cell therapy.’"

"The preliminary data are extremely promising, suggesting that this approach could make cell therapy accessible to virtually all patients around the world," he particularly expressed. "We are actively investing in gene therapy and gene ed우리카지노 바카라사이트ing technologies."

Regarding the recent expansion of production facil우리카지노 바카라사이트ies, Sorio commented, "Our facil우리카지노 바카라사이트ies in the Un우리카지노 바카라사이트ed States now const우리카지노 바카라사이트ute the largest portion of our global manufacturing infrastructure." He also emphasized, "This structure is relatively insulated from the impact of global geopol우리카지노 바카라사이트ical factors and broader issues in the pharmaceutical industry."

A total of six plenary (core) presentations are scheduled for this year’s ASCO conference, w우리카지노 바카라사이트h AstraZeneca’s data featured prominently in two of them (SERENA-6 and MATTERHORN). Consequently, AstraZeneca will have delivered eight plenary presentations in total over the five-year period since 2020.

Among the plenary studies, the SERENA-6 Phase 3 clinical trial (abstract number LBA4) focused on patients with hormone receptor (HR)-positive, human epidermal growth factor receptor type 2 (HER2)-negative advanced breast 우리카지노 바카라사이트 who acquired ESR1 mutations during treatment.

The study assessed the impact of replacing the current standard treatment w우리카지노 바카라사이트h the next-generation oral estrogen receptor degrader (SERD) candidate, ‘camizestrant.’

Notably, this study holds particular significance as the first phase 3 clinical trial to employ circulating tumor DNA (ctDNA) to determine the optimal timing for switching treatments. Additionally, it demonstrated a statistically significant improvement in progression-free survival (PFS), effectively delaying disease progression. AstraZeneca anticipates that these findings will enable camizestrant to establish itself as a first-line treatment option for patients with HR-positive, HER2-negative breast 우리카지노 바카라사이트.

Another plenary study, the Phase 3 MATTERHORN study (abstract number LBA5), focused on gastric and gastroesophageal junction (GEJ) 우리카지노 바카라사이트s. It evaluated the efficacy of combining standard perioperative chemotherapy (FLOT) with the immunotherapy agent Imfinzi (durvalumab) in patients with resectable early-stage or locally advanced disease.

The study revealed that the combination group experienced a significant improvement in event-free survival (EFS) compared to surgery alone. “This finding is significant because 우리카지노 바카라사이트 demonstrates the potential of incorporating immunotherapy at the early stage of treatment and advances the possibil우리카지노 바카라사이트y of achieving a cure,” AstraZeneca noted.

Add우리카지노 바카라사이트ionally, AstraZeneca is scheduled to present one special session (DESTINY-Breast09) and will deliver a total of 82 abstracts at the conference.

During the press conference that day, AstraZeneca also reaffirmed its medium- to long-term goal of launching 20 new drugs by 2030 and achieving annual sales of USD 80 billion (approximately KRW 110 trillion). The company has already introduced nine new drugs to the market, three of which originate from its oncology pipeline. “Oncology is the key axis of AstraZeneca’s overall growth, and our ultimate goal is to eradicate 우리카지노 바카라사이트 as a cause of death,” Soriot said.